Orphazyme A/S
CSE:ORPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orphazyme A/S
Other Long-Term Assets
Orphazyme A/S
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orphazyme A/S
CSE:ORPHA
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Other Long-Term Assets
kr171m
|
CAGR 3-Years
68%
|
CAGR 5-Years
43%
|
CAGR 10-Years
69%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Other Long-Term Assets
kr62m
|
CAGR 3-Years
213%
|
CAGR 5-Years
10%
|
CAGR 10-Years
37%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Other Long-Term Assets
$163k
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Long-Term Assets
kr73.3m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
78%
|
CAGR 10-Years
-7%
|
|
Orphazyme A/S
Glance View
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
